Cargando…
Correction to: Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021–April 2022
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171106/ https://www.ncbi.nlm.nih.gov/pubmed/37180596 http://dx.doi.org/10.1093/ofid/ofad252 |
| _version_ | 1785039357188505600 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10171106 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101711062023-05-11 Correction to: Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021–April 2022 Open Forum Infect Dis Correction Oxford University Press 2023-05-10 /pmc/articles/PMC10171106/ /pubmed/37180596 http://dx.doi.org/10.1093/ofid/ofad252 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | Correction Correction to: Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021–April 2022 |
| title | Correction to: Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021–April 2022 |
| title_full | Correction to: Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021–April 2022 |
| title_fullStr | Correction to: Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021–April 2022 |
| title_full_unstemmed | Correction to: Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021–April 2022 |
| title_short | Correction to: Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021–April 2022 |
| title_sort | correction to: absolute and relative vaccine effectiveness of primary and booster series of covid-19 vaccines (mrna and adenovirus vector) against covid-19 hospitalizations in the united states, december 2021–april 2022 |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171106/ https://www.ncbi.nlm.nih.gov/pubmed/37180596 http://dx.doi.org/10.1093/ofid/ofad252 |